Icatibant Fresenius

Icatibant, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor or factor XII deficiency. It is indicated for rapid symptom relief and reduction of swelling associated with hereditary angioedema attacks.

GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable cold‑chain logistics for this injectable therapy.

Icatibant is used to treat hereditary angioedema by blocking the bradykinin pathway.

- Acute hereditary angioedema (C1‑inhibitor deficiency): rapid reduction of swelling and pain. - Acute hereditary angioedema (factor XII deficiency): rapid reduction of swelling and pain. - Hereditary angioedema attacks in adults: relief of symptoms and restoration of normal function.

Icatibant may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling at injection site: localized erythema. - Nausea: occasional feeling of queasiness. - Headache: transient headache episodes. - Flushing: brief warmth or redness of skin.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or anaphylaxis. - Severe abdominal pain: persistent or worsening abdominal discomfort. - Thrombocytopenia: low platelet count observed in rare cases.

When using Icatibant, several precautions should be observed to ensure safe administration. - Patient assessment: confirm diagnosis of hereditary angioedema and appropriate indication. - Contraindications: avoid use in patients with known hypersensitivity to icatibant or any excipients. - Monitoring: observe for signs of allergic reaction during and after injection. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Concomitant therapy: assess for interactions with ACE inhibitors or other bradykinin‑modulating agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and heighten risk of angioedema. - Angiotensin receptor blockers (ARBs): similar risk of enhanced bradykinin‑mediated effects.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may exacerbate hereditary angioedema severity. - DPP‑4 inhibitors: potential additive effect on bradykinin metabolism. - Other B2 receptor antagonists: may alter therapeutic response.